Antibodies (such as the transferrin receptor monoclonal antibody, TfR mAb) or membrane-disruptive peptides (such as l-valine or trileucine) help penetrate biological barriers to protect nanoconjugates from early degradation and therefore increase the final drug accumulation at the destination; moreover, antisense oligonucleotides (AONs), synthetic DNA oligomers that can form highly sequence-specific hybrids with target RNA, are attached to inhibit the overexpressed laminin-8 in human glioblastoma multiforme (GBM) [104]. The gene discussed is TFRC; the disease is glioblastoma.